Nuwellis announced that Detroit, Michigan-based health system, Henry Ford Health, has begun offering ultrafiltration therapy to heart failure patients suffering from fluid overload using the company’s Aquadex SmartFlow system as part of Nuwellis’ pivotal REVERSE-HF clinical study. “We are excited to study the impact of Aquadex SmartFlow therapy on our heart failure patients who are suffering from severe fluid overload,” said Dr. Jennifer Cowger, Section Head of the heart failure program at Henry Ford. “We are eager to see if ultrafiltration can affect clinical outcomes of our heart failure patients resistant to diuretics. Presently, diuretics are the only options in the field for acute symptoms relief of heart failure congestion. This intervention may change that and could have a longer-term beneficial impact on heart failure too.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUWE:
- Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health
- Nuwellis, Inc. on the Brink: Racing Against Time to Avoid Nasdaq Delisting
- Nuwellis announces results from clinical data anaylses of AVOID-HF trial
- Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference
- Nuwellis reports Q4 EPS ($2.24), consensus ($1.39)
